Cargando…

Overview of the marmoset as a model in nonclinical development of pharmaceutical products

Callithrix jacchus (common marmoset) is one of the more primitive non-human primate species and is used widely in fundamental biology, pharmacology and toxicology studies. Marmosets breed well in captivity with good reproductive efficiencies and their sexual maturity is reached within 18 months of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Orsi, Antonia, Rees, Daryl, Andreini, Isabella, Venturella, Silvana, Cinelli, Serena, Oberto, Germano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126225/
https://www.ncbi.nlm.nih.gov/pubmed/21156195
http://dx.doi.org/10.1016/j.yrtph.2010.12.003
_version_ 1783516102338281472
author Orsi, Antonia
Rees, Daryl
Andreini, Isabella
Venturella, Silvana
Cinelli, Serena
Oberto, Germano
author_facet Orsi, Antonia
Rees, Daryl
Andreini, Isabella
Venturella, Silvana
Cinelli, Serena
Oberto, Germano
author_sort Orsi, Antonia
collection PubMed
description Callithrix jacchus (common marmoset) is one of the more primitive non-human primate species and is used widely in fundamental biology, pharmacology and toxicology studies. Marmosets breed well in captivity with good reproductive efficiencies and their sexual maturity is reached within 18 months of age allowing for rapid expansion of colonies and early availability of sexually mature animals permitting an earlier assessment of product candidates in the adult. Their relatively small size allows a reduction in material requirements leading to a reduction in development time and cost. Fewer animals are also required due to their ability to be used in both pharmacology and toxicology (nonclinical) studies. These factors, alongside a better understanding of their optimal nutrient and welfare requirements over recent years, facilitate the generation of a more cohesive and robust dataset. With the growth of biotechnology-derived pharmaceuticals, non-human primate use has, by necessity, also increased; nevertheless, there is also a growing public call for minimizing their use. Utilizing, the more primitive marmoset species may provide the optimal compromise and once the scientific rationale has been carefully considered and their use justified, there are several advantages to using the marmoset as a model in nonclinical development of pharmaceutical products.
format Online
Article
Text
id pubmed-7126225
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-71262252020-04-08 Overview of the marmoset as a model in nonclinical development of pharmaceutical products Orsi, Antonia Rees, Daryl Andreini, Isabella Venturella, Silvana Cinelli, Serena Oberto, Germano Regul Toxicol Pharmacol Article Callithrix jacchus (common marmoset) is one of the more primitive non-human primate species and is used widely in fundamental biology, pharmacology and toxicology studies. Marmosets breed well in captivity with good reproductive efficiencies and their sexual maturity is reached within 18 months of age allowing for rapid expansion of colonies and early availability of sexually mature animals permitting an earlier assessment of product candidates in the adult. Their relatively small size allows a reduction in material requirements leading to a reduction in development time and cost. Fewer animals are also required due to their ability to be used in both pharmacology and toxicology (nonclinical) studies. These factors, alongside a better understanding of their optimal nutrient and welfare requirements over recent years, facilitate the generation of a more cohesive and robust dataset. With the growth of biotechnology-derived pharmaceuticals, non-human primate use has, by necessity, also increased; nevertheless, there is also a growing public call for minimizing their use. Utilizing, the more primitive marmoset species may provide the optimal compromise and once the scientific rationale has been carefully considered and their use justified, there are several advantages to using the marmoset as a model in nonclinical development of pharmaceutical products. Elsevier Inc. 2011-02 2010-12-13 /pmc/articles/PMC7126225/ /pubmed/21156195 http://dx.doi.org/10.1016/j.yrtph.2010.12.003 Text en Copyright © 2010 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Orsi, Antonia
Rees, Daryl
Andreini, Isabella
Venturella, Silvana
Cinelli, Serena
Oberto, Germano
Overview of the marmoset as a model in nonclinical development of pharmaceutical products
title Overview of the marmoset as a model in nonclinical development of pharmaceutical products
title_full Overview of the marmoset as a model in nonclinical development of pharmaceutical products
title_fullStr Overview of the marmoset as a model in nonclinical development of pharmaceutical products
title_full_unstemmed Overview of the marmoset as a model in nonclinical development of pharmaceutical products
title_short Overview of the marmoset as a model in nonclinical development of pharmaceutical products
title_sort overview of the marmoset as a model in nonclinical development of pharmaceutical products
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126225/
https://www.ncbi.nlm.nih.gov/pubmed/21156195
http://dx.doi.org/10.1016/j.yrtph.2010.12.003
work_keys_str_mv AT orsiantonia overviewofthemarmosetasamodelinnonclinicaldevelopmentofpharmaceuticalproducts
AT reesdaryl overviewofthemarmosetasamodelinnonclinicaldevelopmentofpharmaceuticalproducts
AT andreiniisabella overviewofthemarmosetasamodelinnonclinicaldevelopmentofpharmaceuticalproducts
AT venturellasilvana overviewofthemarmosetasamodelinnonclinicaldevelopmentofpharmaceuticalproducts
AT cinelliserena overviewofthemarmosetasamodelinnonclinicaldevelopmentofpharmaceuticalproducts
AT obertogermano overviewofthemarmosetasamodelinnonclinicaldevelopmentofpharmaceuticalproducts